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Comparison of three methods for diabetes
screening in a rural clinic in Honduras
John D. Piette,1,2 Evan C. Milton,1,2 Allison E. Aiello,3,4
Milton O. Mendoza-Avelares,5 and William H. Herman2,3
Objective. To evaluate two alternatives to the fasting plasma glucose (FPG) test for dia-
betes screening in Latin America.
Methods. Eight hundred adults without diabetes were recruited in a primary care clinic in
Honduras. An equation-based screening formula, incorporating a random capillary glucose
test and other risk factors, was used for initial screening. All patients with a screening-based
probability of diabetes ≥ 20%, plus one-fifth of those with a probability < 20%, were asked to
return for FPG and point-of-care hemoglobin A1c (POC-A1c) tests. An FPG ≥ 126 milligrams
per deciliter and a POC-A1c ≥ 6.5% were used as gold standards to assess the performance of
the screening equation. The association between the POC-A1c and the FPG tests was exam-
ined as were patient factors associated with failure to return for follow-up and variation in di-
abetes risk across subgroups.
Results. The screening equation had excellent test characteristics compared with FPG and
POC-A1c. Using the FPG gold standard, the POC-A1c had a sensitivity of 77.8% and a speci-
ficity of 84.9%. With an A1c cutoff of 7%, POC-A1c specificity increased to 96.2%. Thirty-
four percent of patients asked to return for follow-up testing failed to do so. Those who failed
to return were more likely to be men and to have hypertension.
Conclusions. Both the screening equation and POC-A1c are reasonable alternatives to an FPG
test for identifying patients with diabetes. Given the barriers to currently recommended screening
procedures, these options could have important public health benefits in Latin America.
Diabetes mellitus, type 2; rural population; diagnosis; diagnostic techniques and pro-
cedures; Honduras.
ABSTRACT
The global prevalence of diabetes mel-
litus is expected to double from 171 mil-
lion to 366 million between 2000 and
2030, and developing countries will likely
experience 80% of this burden (1, 2).
Many countries in Latin America are wit-
nessing an epidemiologic transition that
is a fundamental cause of their growing
diabetes epidemic (3). In particular, with
the success of efforts to control communi-
cable diseases and a demographic shift to
lower fertility, the Honduran population
is aging (3, 4). Lifestyle changes, such as
less physical activity, are being docu-
mented throughout Latin America as a
result of migration from rural to urban
areas (1, 5). Moreover, direct foreign in-
vestment in the food sector and profits
from heavily marketed processed foods
and beverages have pushed Latin Amer-
ica into a nutrition transition from tradi-
tional diets toward diets rich in fats,
sugar, and salt (1, 2). 
Recent statistics demonstrate that rates
of type 2 diabetes are increasing in Hon-
duras. A study in the capital city of Tegu-
cigalpa in 2003–2004 put the adult preva-
lence at 7.8% and indicated that 42% of
people with the disease were unaware of
their condition (6). This prevalence esti-
mate is consistent with that reported in
other large Latin American cities (e.g.,
4.5% in Lima and 9.5% in Mexico City in
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2005) (7). In 2003, Honduras incurred so-
cial costs of diabetes (including lifetime
forgone earnings due to premature mor-
tality and disability) that approached 
US $126 million and direct medical costs
of nearly $114 million (5). In a country
where more than 87% of health care pay-
ments are out of pocket (8) and where
diabetes-reporting programs are rare 
and underestimate the true prevalence of
disease (6), the economic burden of dia-
betes is likely to be tremendous.
Currently, the American Diabetes Asso-
ciation recommends screening for type 2
diabetes if an individual has one or more
of the following risk factors: diabetes
diagnosed in a first-degree relative, hy-
pertension, cardiovascular disease, lipid
metabolism disorders, obesity (body mass
index (BMI) > 27 kilograms per meter
squared), history of gestational diabetes,
or age greater than 45 years (9). However,
there is little consensus about the most ef-
fective and efficient means of screening in
developing countries that lack compre-
hensive health systems or adequate cover-
age for health care (10). In such areas, the
lack of access to screening and diagnostic
services may result in missed opportuni-
ties to detect diabetes (11).
According to the World Health Organi-
zation, the 75-gram oral glucose tolerance
test (OGTT) remains the gold standard
for diagnosing diabetes. However, the
OGTT is difficult to implement and pro-
hibitively costly for resource-poor health
care systems (12–14). Many authorities
prefer fasting plasma glucose (FPG) as 
a diagnostic test because it is more con-
venient for the patient than OGTT, less
costly and time-consuming, and has su-
perior repeat-test reproducibility (14).
However, FPG testing often requires a
second visit to ensure that the patient is
fasting. The added out-of-pocket costs of
those visits and the logistic burden may
mean that large numbers of diabetes pa-
tients go unidentified (14), even if tests
are free of charge (11, 15). 
Laboratory-based glycosylated hemo-
globin (A1c) testing has recently been
recommended for diabetes screening by
the American Diabetes Association, the
European Association for the Study of
Diabetes, and the International Diabetes
Federation (14). Laboratory A1c tests are
an attractive alternative to the FPG, be-
cause they do not require that the patient
fast and they may provide more stable
results given fluctuations in FPG concen-
trations (14). However, as with other
laboratory-based measures, A1c testing
may be unavailable in Latin American
clinics with inadequate resources geo-
graphically distant from testing centers. 
One alternative to lab-based A1c is the
point-of-care A1c test (POC-A1c). A vari-
ety of POC-A1c devices are available, em-
ploying assays certified by the Diabetes
Control and Complication Trial/National
Glycohemoglobin Standardization Pro-
gram and the International Federation of
Clinical Chemistry (16). However, POC-
A1c has not been recommended as a sub-
stitute for lab-based A1c tests because of
concerns about quality control and the
variability in POC instruments (16). Nev-
ertheless, POC-A1c may be an important
alternative to lab-based A1c tests, espe-
cially for patients facing financial or
transportation constraints (17). A study
comparing a POC-A1c with a lab-based
A1c test showed a sensitivity of 81.8%
and a specificity of 93.3% when using a
POC-A1c cut point of 7% (18). To date, no
POC-A1c test has been validated in Latin
America.
In addition to the POC-A1c, a number
of clinical strategies have been devel-
oped to predict patients’ levels of glyce-
mia and identify undiagnosed diabetes
(19–27). All these strategies have in-
volved some type of multivariate model
to combine risk factor information into
an overall index of patients’ probability
of disease. While most screening models
use risk factors such as age, sex, BMI,
blood pressure, and family history of
diabetes, models limited to these char-
acteristics often show only moderate 
test specificity. In contrast, a screening
model that includes random capillary
glucose data is associated with lower
false-positive rates (13, 22). This model
provides a substantial advantage in set-
tings where a false-positive result can
burden the individual and lead to over-
use of scarce clinical resources. One par-
ticular screening algorithm developed
by Tabaei et al. has shown excellent test
characteristics in North America and
Egypt (13, 22). In a prior brief report (28),
this clinical equation was found to be re-
liable within a population of primary
care patients in Honduras compared
with the FPG method. Compared with
other risk scores and predictive equa-
tions whose specificity have ranged from
55% to 78%, the specificity of the equa-
tion using random capillary glucose as a
predictor is 96% to 97% with an FPG
gold standard (11, 22).
As a follow-up to the prior brief report
(28), this study presents the results of a
three-way comparison of alternative
methods for diabetes screening in rural
clinics in Latin America: FPG testing,
POC-A1c testing, and the use of a risk
equation based on a random capillary
blood sample. Also, the requirement of a
follow-up clinic visit, which is typically
necessary for FPG testing, was studied
as a potential barrier to diabetes screen-
ing. Finally, the variation in patients’
sociodemographic characteristics and
clinical risk factors across subgroups
with different levels of diabetes risk was
examined.
MATERIALS AND METHODS
Setting, population, and sampling
The study was conducted between
June and August 2008 in a primary care
clinic in Yojoa International Medical Cen-
ter, in Santa Cruz de Yojoa in central
Honduras. The clinic serves a population
of approximately 15 000 adult and pedi-
atric patients from rural and semirural
areas. Eight hundred study participants
without a diagnosis of diabetes (self-
report) were recruited for the initial
screening. Patients were eligible if they
had nonurgent medical visits, were 18
years or older, were not pregnant, and
had not had a heart attack in the three
months preceding participation (26). Par-
ticipants were initially approached in the
clinic waiting area and men were given
selection preference because of limited
representation in the clinical population.
All patients provided informed consent.
Patients completed a baseline survey and
nonfasting blood glucose testing at the
time of recruitment (as described below).
A subset of patients were asked to return
to the clinic for FPG and POC-A1c tests.
The study was reviewed and approved
by the University of Michigan Institu-
tional Review Board.
Initial screening
At the time of recruitment, eligible pa-
tients completed a survey, and a capillary
random blood glucose test was per-
formed with an Accu-Chek Aviva capil-
lary glucose meter (29). These data were
used to calculate participants’ equation-
based risk of diabetes with coefficient
weights developed and reported previ-
ously (13). The survey was administered
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in a face-to-face interview and partici-
pants were asked questions about demo-
graphic characteristics and recognized
diabetes risk factors, including their edu-
cation level, household income, number
of people living in the household, rela-
tive wealth (30, 31), family history of dia-
betes (21), and history of giving birth to a
macrosomic infant (> 4 500 grams) (32).
Basic clinical measurements not requir-
ing laboratory analysis were recorded,
including BMI with height and weight
measured while the patient wore light
clothing and no shoes. Blood pressure
was recorded with a standard mercury
sphygmomanometer after 5 minutes of
rest and as the average of two measure-
ments. Waist circumference was mea-
sured midway between the lowest rib
and the iliac crest (19). Self-reported post-
prandial time was recorded as the num-
ber of hours since the participant re-
ported last eating or drinking anything
other than water. Survey responses and
clinical measurements were used to cal-
culate patients’ probability (p) of diabetes
according to the following Tabaei et al.
logistic regression (22) equation:
p(diabetes) = 1/[1 + exp(–X)]; X = –10.0382
+ 0.0331 × age + 0.0308 × random capil-
lary glucose + 0.25 × self-reported post-
prandial time + 0.562(female) + 0.0346 
× BMI.
Patients’ risk was reported back to
them along with general information
about diabetes risk factors and how they
could modify their risk through behav-
ioral changes.
Follow-up glucose testing 
All participants with a screening-
equation-based probability of diabetes 
> 20% were asked to return for addi-
tional evaluation including FPG and
POC-A1c tests. Additionally, every fifth
participant with a screening-equation-
based probability of diabetes < 20% was
asked to return for follow-up testing. Pa-
tients selected for later evaluation were
instructed to return to the clinic at least
24 hours after their initial visit, having
fasted (no food or beverages other than
water) for at least 8 hours. Participants
who returned received a monetary in-
centive equivalent to US $5. 
At the follow-up visit, FPG was mea-
sured with the HemoCue 200 glucose an-
alyzer. This portable unit is widely rec-
ognized as a preferred laboratory refer-
ence and is intended for screening and
diagnosing diabetes mellitus (33). FPG
was measured with 10 microliters (μL) of
capillary whole blood derived from a
finger stick. The World Health Organiza-
tion, International Diabetes Federation,
and American Diabetes Association rec-
ognize FPG of equal to or greater than
126 milligrams per deciliter (mg/dL) (7.0
millimoles per liter) as diagnostic of dia-
betes (14, 33, 34).
To measure A1c, the Bio-Rad Labora-
tories in2it A1c point-of-care analyzer
was used (16, 35). The in2it assay re-
quires 10 µL of capillary blood from a
fingerstick and uses boronate affinity
chromatography to provide results that
are free from hemoglobin variant inter-
ference and traceable to the Diabetes
Control and Complications Trial ref-
erence (http://www.bio-rad.com/). In
2009, a study in Singapore showed that
the in2it assay had a satisfactory total
precision (coefficient of variance) of < 5%
and performed better than some other
POC-A1c devices (35). As recognized 
by multiple professional guidelines (14),
a POC-A1c of ≥ 6.5% was considered
highly suggestive of diabetes and in-
creased risk of microvascular complica-
tions. At follow-up, patients with an FPG
result ≥ 126 mg/dL or an A1c ≥ 6.5%
were referred to one of the onsite physi-
cians for diabetes counseling and further
diagnostic evaluation.
Analysis
Initial analyses compared the sociode-
mographic characteristics of participants
who returned for confirmatory diagnos-
tic testing and those who were asked to
return but did not. For these analyses, a
Pearson’s χ2 test was used for categorical
variables and a Student’s t-test was used
for continuous variables. Among the
subset of patients asked to return for
follow-up testing (n = 200), logistic re-
gression models were constructed to
identify sociodemographic and clinical
characteristics independently associated
with returning for follow-up and con-
trolling for patients’ baseline screening-
equation-based diabetes risk score.
In general, the analytic process for
evaluating the screening measures was
as follows: Step 1, calculate a continuous
probability of diabetes based on data col-
lected during the initial screening and the
screening equation; Step 2, use these data
with the 20% risk cutoff to identify a sam-
ple for follow-up that represented a
broad range of continuous screening risk
scores; Step 3, on the basis of the sample
at follow-up, calculate the sensitivity and
specificity of the continuous screening
score and POC-A1c results across the
scores’ entire continuous ranges and plot
those sensitivity-specificity results using
receiver-operator characteristic (ROC)
curves; and Step 4, on the basis of those
curves, identify the ideal cutoff for each
measure and the sensitivity and speci-
ficity at those cut points.
The prognostic significance of the
screening equation was validated against
two gold standards: FPG > 126 mg/dL
and POC-A1c > 6.5% (14, 15). Results
from the comparison of the screening
equation with FPG were reported pre-
viously (28) but are repeated here to
compare them with the screener perfor-
mance when evaluated against the POC-
A1c gold standard. The ROCFIT pro-
cedure within STATA was used to fit
maximum-likelihood ROC curves by
plotting the sensitivity of screening
scores against the false-positive rate (1 –
specificity). The method originally de-
veloped by Dorfman and Alf (36) and
the ROCCOMP procedure were used to
compare the area under the screening
equation curves (the measure of the
screening equation’s validity) using both
the FPG and POC-A1c results. The POC-
A1c test was then evaluated as an alter-
native to the laboratory-based A1c by
constructing a separate ROC curve com-
paring various POC-A1c cut points
against the FPG gold standard.
In additional analyses, all 800 recruited
patients were assigned to levels of dia-
betes risk according to their initial screen-
ing equation and POC-A1c test results.
Group 1 (low-risk) patients included
subjects who were either “low-risk con-
firmed” (screening-equation-based risk 
< 20% and POC-A1c < 6.5%) or “low-
risk unconfirmed” (screening-based risk 
< 20% without a confirmatory POC-A1c).
Group 2 (high-risk) patients included
subjects who were either “high-risk un-
confirmed” (screening-equation-based
risk ≥ 20% but no confirmatory POC-
A1c) or “high-risk confirmed” (equation-
based risk ≥ 20% and POC-A1c ≥ 6.5%).
Between-group and within-group com-
parisons of patients’ sociodemographic
characteristics and other risk factors were
conducted with χ2 and Student’s t-test.
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RESULTS
Patient recruitment and follow-up
Eight hundred participants were re-
cruited including 266 (33.2%) men and
534 (66.8%) women. Mean age was 38.5
years and patients lived an average 10.5
kilometers (6.5 miles) from the clinic.
Average monthly household income was
US $319. Figure 1 provides basic descrip-
tors of the 800 participants based on their
glycemic test results and whether they
returned for follow-up evaluation. Of the
original sample, 67 patients (8.4%) were
identified by the screening equation as
having a 20% or greater risk of diabetes
and were asked to return for confirma-
tory testing. The remaining 733 patients
were found to have a < 20% risk, and
one-fifth of them (n = 133) were asked to
return for confirmatory FPG and A1c
tests. Two-thirds (66.5%) of all patients
asked to participate in follow-up testing
returned to the clinic, with no difference
in the proportion returning between
those with an initial risk of ≥ 20% versus
< 20%. In logistic regression models ex-
amining the factors predictive of return-
ing for follow-up among all patients
asked to return (n = 200), those who
failed to return for follow-up were more
likely to be male (adjusted odds ratio
(AOR) = 2.9, 95% confidence interval 
(CI) = 1.4–6.2) and to have hypertension
(AOR = 2.3; 95% CI = 1.0–5.3). Among the
subset of patients initially identified with
a 20% or greater risk of diabetes (n = 67),
those who failed to return for follow-up
were more likely to be men (AOR = 13.6,
95% CI = 1.0–181.4) and to have hyper-
tension (AOR = 7.1, 95% CI = 1.1–50.0).
Predictive validity of the screening
equation using the two gold standards
As reported previously, the screening
instrument had good predictive accuracy
compared with the gold standard of an
FPG ≥ 126 mg/dL (Figure 2) (28). The
overall area under the curve (AUC) was
0.89 (95% CI = 0.80–0.98). Overall classifi-
cation accuracy was maximized by using
a p(diabetes) value of 0.42. With that cri-
terion, 74% of all patients with diabetes
confirmed by FPG were correctly classi-
fied by the screening equation (i.e., a sen-
sitivity of 74%), and 97% of patients with-
out diabetes were correctly identified by
the screening equation (specificity of
97%). With the 0.42 cut point and assum-
ing a diabetes prevalence of 7.4% (the best
estimate based on this sample), the test
had a positive predictive value of 68%
and a negative predictive value of 98%.
Using a gold standard of a POC-A1c
result ≥ 6.5%, the screening equation
maintained good predictive accuracy,
with an AUC of 0.87 (Figure 2; 95% CI =
0.81–0.94). A χ2 test comparing screening
performance using the two gold stan-
dards identified no significant difference
between the AUCs (p = 0.82). Consider-
ing the same 0.42 screening cut point and
using the POC-A1c gold standard, the
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FIGURE 1. Flow of study participants through initial screening and confirmatory diabetes testing. Cell entries are No. (%) or mean ± standard
deviation. DM = diabetes mellitus, FPG = fasting plasma glucose, mg/dl = milligrams per deciliter, M = male, F = female, km = mean distance from
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screener showed a lower sensitivity
(54%) than when compared with the
FPG but the same specificity (97%). On
the basis of the POC-A1c gold standard,
the screening equation had a positive
predictive value of 57% and a negative
predictive value of 96%.
Comparing POC-A1c results with
FPG results
Of patients who returned for follow-
up, 27 had a FPG ≥ 126 mg/dL, and 37
had an A1c ≥ 6.5% for a total of 43 pa-
tients who tested positive on one or the
other test. Of this group, 21 participants
tested positive with both FPG and POC-
A1c, and 22 participants were identified
with one test but not the other. Specif-
ically, 16 patients with an A1c ≥ 6.5%
were not identified by the FPG test, and 6
patients with an FPG ≥ 126 mg/dL were
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FIGURE 2. Receiver operator characteristic curves evaluating sensitivity and specificity of the
diabetes screening equation against the fasting plasma glucose (FPG) and point-of-care hemo-
globin A1c (POC-A1c) gold standards. Diagonal reference line defines points where the test
would predict diabetes no better than by chance. Sensitivity and specificity of the screening ins-
trument were calculated using as gold standards an FPG of ≥ 126 milligrams per deciliter and 
a POC-A1c ≥ 6.5%. The areas under the FPG and POC-A1c curves were not statistically different















FPG Area under curve = 0.887 se(area) = 0.046
POC—A1c Area under curve = 0.874 se(area) = 0.03
Reference
FIGURE 3. Receiver operator characteristic curve evaluating sensitivity and specificity of the
point-of-care hemoglobin A1c (POC-A1c) test against the fasting plasma glucose (FPG) gold
standards. Gray band represents 95% confidence interval. Diagonal reference line defines points
where the test would predict diabetes no better than by chance. Sensitivity and specificity of the
POC-A1c test were calculated using an FPG of ≥ 126 milligrams per deciliter as the gold standard.
Dashed horizontal lines highlight the sensitivity and specificity for cutpoints of POC-A1c ≥ 6.5%
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not identified by the POC-A1c. Using the
FPG test as a gold standard and the rec-
ommended A1c cutoff of ≥ 6.5%, the
POC-A1c had a sensitivity of 78% and a
specificity of 85%. With an A1c cutoff of
7%, sensitivity decreased slightly (to
74.1%) but specificity increased substan-
tially (96%). Figure 3 shows the perfor-
mance of the POC-A1c test against the
gold standard of FPG ≥ 126 mg/dL.
Variation in patient characteristics
across diabetes risk levels
Table 1 illustrates the variation in pa-
tient characteristics across the four sub-
groups with increasing risk of diabetes
as determined by their initial screening
result and (for those returning for follow-
up) POC-A1c test findings. Between
low-risk (Group 1) and high-risk (Group
2) groups, significant differences were
observed in the proportion of patients
with a physician-diagnosed blood pres-
sure problem, use of antihypertensive
medication, levels of physical activity,
educational attainment, employment
status, number of children, waist circum-
ference, and blood pressure. Within the
high-risk group (Group 2), those who
failed to return for follow-up had higher
systolic blood pressure (mean = 131
mmHg vs. 121 mmHg, p < 0.0001). Dia-
stolic values of those who failed to re-
turn for follow-up also were higher, al-
though the result was not statistically
significant (mean diastolic = 78 mmHg
vs. 71 mmHg, p = 0.11).
DISCUSSION
Type 2 diabetes poses a growing
health threat to Honduras and to much
of Latin America due to the epidemio-
logic transition from communicable to
chronic diseases (1). Many people with
diabetes go undiagnosed until a major
health event such as cardiovascular dis-
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TABLE 1. Characteristics of study participants according to estimated diabetes risk based on initial screening and confirmatory testing (POC-A1c ≥ 6.5%)
for returning subjects (n = 800)
Group 1 (Low risk) Group 2 (High risk)
Confirmed Unconfirmed Confirmed Unconfirmed
DM negativea DM negativeb DM positivec DM positived
Characteristic No. = 96 No. = 645 No. = 37 No. = 22 P e
Age 42.9 ± 16.9f 36.8 ± 14.6 49.9 ± 10.8f 56.5 ± 12.2 N/A
Sex N/A
Male 17 (17.7)g 236 (36.6) 7 (18.9) 6 (27.3)
Female 79 (82.3)f 409 (63.4) 30 (81.1) 16 (72.7)
Physician diagnosed BP
Problems 23 (23.9) 154 (23.9) 17 (45.9) 13 (61.9) < 0.0001
Taking BP medication 12 (12.8) 52 (8.1) 7 (18.9) 8 (38.1) < 0.0001
Weekly physical activity 0.014
None 5 (5.21)g 44 (6.8) 5 (13.5) 4 (19.1)
Some activity 59 (61.5) 313 (48.5) 21 (56.8) 13 (61.9)
Vigorous activity = 2× 18 (18.8) 132 (20.5) 5 (13.5) 13 (61.9)
Vigorous activity > 2× 14 (14.6) 156 (24.2) 6 (16.22) 3 (14.3)
Oral inflammation 34 (35.8) 300 (46.9) 13 (35.1) 6 (28.6) 0.061
Years of school 0.036
None 16 (16.7)g 70 (10.9) 5 (13.5) 7 (33.3)
1–6 57 (59.4) 334 (51.9) 24 (64.9) 9 (42.9)
7–9 9 (9.4) 66 (10.3) 3 (8.1) 3 (14.3)
10–12 7 (7.3)f 124 (19.3) 5 (13.5) 2 (9.5)
13 or more 7 (7.3) 50 (7.8) 0 (0) 0 (0)
Worked in past 12 months 38 (39.6)f 379 (58.9) 16 (43.2) 8 (38.1) 0.026
Number of children < 0.0001
None 10 (10.4)g 118 (18.3) 2 (5.4) 1 (4.8)
1–3 44 (45.8) 294 (45.6) 11 (29.7) 3 (14.3)
4–6 22 (22.9 ) 144 (22.3) 11 (29.7) 8 (38.1)
≥ 7 20 (20.8 )f 89 (13.8) 13 (35.1) 9 (42.9)
Household income
Male 27.5 ± 5.1 27.0 ± 5.3 31.1 ± 1.5 31.8 ± 4.0
Female 27.9 ± 5.5 28.0 ± 6.2 29.8 ± 5.5 30.6 ± 6.1
Waist circumference (cm)
Male 89.7 ± 11.5 90.7 ± 13.6 106.5 ± 5.3 105.3 ± 5.6 < 0.0001
Female 87.2 ± 11.1 86.1 ± 12.7 93.0 ± 10.8 95.1 ± 13.0 0.0001
Postprandial time (hours) 4.6 ± 3.5g 3.3 ± 2.5 4. 2 ± 3.2 5.6 ± 4.3 N/A
Systolic BP (mmHg) 113.2 ± 23.6 113.6 ± 17.6 121.1 ± 14.9f 131.4 ± 23.7 < 0.0001
Random glucose (mg/dL) 106.3 ± 29.9f 100.7 ± 18.2 210.2 ± 111.1 202.7 ± 116.5 N/A
FPG (mg/dL) 96.5 ± 14.1 … 167.7 ± 91.4 … < 0.0001
HbA1c (%) 5.8 ± 0.4 … 9.0 ± 2.4 … < 0.0001
Data are: means ± standard deviation or No. (%); POC-A1c = point-of-care hemoglobin A1c; DM = diabetes mellitus; N/A = not applicable; BP = blood pressure; BMI = body mass index; cm =
centimeters; mmHg = millimeters of mercury; mg/dL = milligrams per deciliter; FPG = fasting plasma glucose; HbA1c = glycosylated hemoglobin; . . . indicates no data are available.
a Screening p (DM) < 20% and HbA1c ≤ 6.5%.
b Screening p (DM) < 20% and no HbA1c.
c Screening p (DM) ≥ 20% and HbA1c ≥ 6.5%.
d Sreening p (DM) ≥ 20% and no HbA1c.
e Student’s t test for continuous variables and χ2 test for categorical variables, performed between groups one and two. 
f Significance of < 0.05 within groups, either one or two.
g Significance of < 0.0001 within groups, either one or two.
ease manifests (1–6, 8, 10, 33). Therefore,
it is critical that a simple, noninvasive,
and inexpensive means of recognizing
individuals at increased risk for diabetes
be identified for use in these at-risk pop-
ulations. This study evaluated two op-
tions: (1) a formula-based screening tool
that includes a random capillary glucose
test, information about postprandial
time, and basic information about other
risk factors; and (2) a POC-A1c test. With
respect to the screening equation, com-
parisons of the area under the ROC in
this study with prior studies of the same
screening tool show that the equation
performed at least as well if not better in
Honduras as in other parts of the world.
Specifically, when the model was devel-
oped in Egypt in 2002, the ROC analyses
showed an AUC of 0.88 (compared with
0.89 and 0.87 in this study). When the
model was validated in a U.S. popula-
tion in 2005, it was associated with an
AUC of 0.82 (13, 22). No statistical differ-
ence was found between results evaluat-
ing the screening equation against the
FPG and the POC-A1c tests.
The POC-A1c had good test character-
istics compared with the internationally
recognized standard of the FPG. As the
use of POC-A1c devices becomes more
feasible in busy clinical settings, it is im-
portant that the less-than-ideal precision
of these devices and the differences with
laboratory reference methods be under-
stood by the users (16). POC-A1c is an
imperfect predictor of undiagnosed dia-
betes yet some correlation with labora-
tory A1c and other gold standards re-
duces some of the uncertainty. In this
study, it was found that the internation-
ally recommended cutoff of 6.5% may
maximize test sensitivity but at the price
of a false-positive rate in excess of 15%.
In resource-constrained health systems,
a POC-A1c cutoff of 7% should be con-
sidered, as this study found it to have a
false-positive rate of < 4% with only a
slightly lower sensitivity. Repeated test-
ing using that threshold may increase
the sensitivity for a given patient over
time while still avoiding the investment
of clinical resources for confirmatory
testing based on a false-positive screen-
ing result.
Individuals of lower socioeconomic
status were found to be at higher risk of
undiagnosed diabetes. Patients who had
limited education, had not worked in the
past year, and had lower household in-
come were more likely to be in the high-
risk group. Targeting these individuals is
far more feasible with an inexpensive
screening tool that provides results in 
a single visit than one that requires a
follow-up visit. A large proportion of pa-
tients (including as many as 35% identi-
fied as high risk based on their screening
results) did not return for those follow-
ups and therefore were not appropriately
diagnosed. Those who failed to return
were not a random subset of the at-risk
population. Specifically, the odds of not
returning for confirmatory testing were
significantly higher for males and for in-
dividuals with hypertension. These pa-
tients may have been more likely to miss
their follow-up visits because of work
commitments, less appreciation of the
importance of managing asymptomatic
conditions such as diabetes, or other rea-
sons. Because these groups are at height-
ened risk for undiagnosed diabetes and
diabetes complications, the alternative
screening methods suggested by this
study may help to target those subgroups
with especially poor outcomes.
More generally, screening methods
that do not require follow-up fasting vis-
its may substantially improve the accessi-
bility of care for rural patients in Latin
America. In an unpublished survey of
the same clinic population, we found that
43% of patients with chronic illnesses re-
ported having to cancel a clinic appoint-
ment at least once in the prior year
because of transportation problems.
Services that require fewer face-to-face
encounters could dramatically improve
the impact of health education. More-
over, in the context of scarce resources,
services that can identify undiagnosed
diabetes patients and begin disease man-
agement early could prevent complica-
tions, thereby lowering overall acute care
costs. In communities where there are
few employment options for individuals
with functional limitations due to neu-
ropathy, retinopathy, or other diabetes-
related disorders, such early detection
programs may increase the overall pro-
ductivity of the population, thereby
boosting the economy and lessening re-
liance on aid such as remittances from
relatives living abroad.
At present, the practicalities of imple-
menting a diabetes screening program
are unresolved, especially in resource-
poor areas of the world (37). Individual
countries should attempt to develop and
evaluate setting-specific diabetes risk
identification and prevention strategies
based on available resources (37). Con-
venient, informative clinical measures
like POC-A1c testing and equation-
based screening may encourage partici-
pation and improve rates of appropriate
treatment initiation (15). The specifics
about which screening method should
be used and for whom will depend on
factors such as the true prevalence of un-
diagnosed diabetes, the cost of diagnos-
tic testing, and treatment availability for
those identified as having disease.
A limitation of this study is possible
selection bias introduced in the initial
stage of participant selection. Research-
ers approached all potential participants
in the clinic waiting room but it was not
done at random. While this procedure
may bias estimates of the prevalence of
diabetes, it is unlikely that it would in-
fluence the overall performance of the
screening tests or the association be-
tween patients’ likelihood of having dia-
betes and other risk factors such as their
BMI or blood pressure. However, it
should be stressed that because this sam-
ple is not an entirely representative one,
these results cannot be used to predict
the prevalence of undiagnosed diabetes
within the greater Honduran popula-
tion. Additionally, the FPG test was
given only once to each returning partic-
ipant and was not administered twice, as
is recommended for eliminating some of
the fluctuations in glucose concentra-
tions. This factor may account for some
of the lack of overlap in the FPG versus
POC-A1c positive outcomes. Finally,
prior studies have found variation in the
performance of POC-A1c devices (15)
and only one such device was used here.
Further study, including the use of mul-
tiple POC-A1c tests in the same popula-
tion, would help to confirm the estimates
reported here.
With these caveats, it can be con-
cluded that the screening equation based
on a random capillary glucose test and
the POC-A1c are reasonable alternatives
to laboratory-based A1c and FPG tests
for identifying patients with diabetes in
rural clinics in Latin America. These al-
ternatives should be given serious con-
sideration, as laboratory A1c testing is
often unavailable in resource-poor areas
and FPG testing may miss large numbers
of patients most at risk because of the
need to return for a fasting visit and be-
cause of their low socioeconomic status.
These alternatives may be particularly
important in Latin America, because pa-
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Objetivo. Evaluar dos alternativas a la prueba de glucemia en ayunas para el tami-
zaje de la diabetes en América Latina. 
Métodos. Se seleccionaron 800 adultos sin diabetes que acudían a un dispensario de
atención primaria en Honduras. Para el tamizaje inicial se utilizó una fórmula de ta-
mizaje mediante la aplicación de ecuaciones, que incluía una prueba aleatoria de la
concentración de glucosa capilar y otros factores de riesgo. A todos los pacientes
cuyos tamizajes revelaron una probabilidad de diabetes ≥ 20%, y a una quinta parte
de los pacientes con una probabilidad < 20%, se les solicitó que regresaran para un
examen de glucemia en ayunas y para una de glucohemoglobina (HbA1c) en el lugar
de atención. Se utilizaron los siguientes criterios de referencia para evaluar el desem-
peño de la ecuación del tamizaje: glucemia en ayunas ≥ 126 mg por decilitro y HbA1c
≥ 6,5%. Se analizó la asociación entre las prueba de HbA1c y la de glucemia en ayu-
nas, así como los factores de los pacientes asociados con faltas a las citas de segui-
miento y la variación del riesgo de diabetes a través de los subgrupos.  
Resultados. La ecuación de tamizaje presentó excelentes características de análisis
en comparación con el examen de glucosa en ayunas y con la prueba de HbA1c.
Usando el criterio de referencia del examen de glucosa en ayunas, el HbA1c mostró
una sensibilidad de 77,8% y una especificidad de 84,9%. Con un límite de A1c de 7%,
la especificidad de la prueba de HbA1c aumentó a 96,2%. No se presentaron para el
seguimiento de la prueba 34% de los pacientes a quienes se les solicitó que regresa-
ran. La probabilidad de no regresar para el seguimiento fue mayor en hombres y que
tenían hipertensión. 
Conclusiones. Tanto la ecuación de tamizaje como la prueba HbA1c son alternativas
razonables al examen de glucosa en ayunas. Teniendo en cuenta las barreras actuales
a la aplicación de los procedimientos de tamizaje recomendados, estas opciones po-
drían representar beneficios importantes para la salud pública en América Latina. 
Diabetes mellitus tipo 2; población rural; diagnóstico; técnicas y procedimientos diag-
nósticos; Honduras.
RESUMEN
Comparación de tres métodos
para el tamizaje de la diabetes
en un consultorio rural 
en Honduras
Palabras clave
